SCHEMBL25254093

SCHEMBL25254093

Cc1nc(Cl)c([N+](=O)[O-])c(Cl)c1Br

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
TSHR P16473 2/20 0.35
MAPT P10636 2/20 0.34
PKM P14618 1/20 0.33
ALDH1A1 P00352 4/20 0.31
TDP1 Q9NUW8 3/20 0.31
DCTPP1 Q9H773 3/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31
GRIN3A Q8TCU5 1/20 0.31
MAPK1 P28482 1/20 0.31
CYP1A2 P05177 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31135897 1.00 POLB (0.36) POLBTSHRMAPTPKMALDH1A1
SCHEMBL11374067 0.87 MAPT (0.38) POLBTSHRMAPTPKMALDH1A1
SCHEMBL1624952 0.85 POLB (0.39) POLBTSHRMAPTPKMALDH1A1
SCHEMBL31539787 0.82 TSHR (0.39) POLBTSHRMAPTPKMALDH1A1
SCHEMBL843365 0.81 TSHR (0.42) POLBTSHRMAPTPKMALDH1A1
SCHEMBL13424740 0.81 MAPT (0.38) TSHRMAPTPKMALDH1A1TDP1
SCHEMBL31135887 0.80 POLB (0.36) POLBMAPTPKMALDH1A1TDP1
SCHEMBL25289123 0.80 POLB (0.36) POLBMAPTPKMALDH1A1TDP1
SCHEMBL31260410 0.78 POLB (0.36) POLBTSHRMAPTPKMALDH1A1
SCHEMBL13939169 0.75 POLB (0.41) POLBTSHRMAPTPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171464-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2025-05-29 US disclosed
US-12275745-B2 Therapeutic compounds and methods of use GENENTECH, INC. (US) 2025-04-15 US disclosed
EP-4436969-A2 BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER Genentech, Inc. (US) 2024-10-02 EP disclosed
US-20230203062-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 US disclosed
US-20230203062-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 US disclosed
US-20230203062-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 US disclosed
WO-2023097194-A2 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-01 WO disclosed
WO-2023097194-A2 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171464-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 POLB 1101/4885TSHR 4446/4885MAPT 411/4885
US-20230203062-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 POLB 1101/4885TSHR 4446/4885MAPT 411/4885
US-12275745-B2 Therapeutic compounds and methods of use VHL, TP53, MCL1 POLB 1101/4885TSHR 4446/4885MAPT 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.